Abstract 6875: Preclinical development of a novel small molecule multitarget inhibitor LCI133 for endometrial adenocarcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6875
Abstract: Endometrial cancer (EC) is the most common gynecologic malignancy with rising mortality and limited targeted therapies. LCI133, an in silico-designed triple inhibitor of CDK4/6-CDK9-AURK, has demonstrated nano-molar potency against PTEN-mutant EC cells lines and favorable… read more here.
Keywords: cancer; pgr cre; inhibitor; endometrial adenocarcinoma ... See more keywords